Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > non alcoholic steatohepatitis treatment market
Get a free sample of Non-alcoholic Steatohepatitis Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Non-alcoholic Steatohepatitis Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The non-alcoholic steatohepatitis (NASH) treatment market is experiencing robust growth due to continuous innovation and technological advancements. This market expansion is fuelled by leading companies in the healthcare sector that are striving to provide a diverse range of advanced treatments, including both medications and innovative therapies. These companies are consistently investing in research and development to introduce new products and enhance existing ones.
The company profile section includes both companies that have commercial drug available in the market as well as those that are in the clinical development phase. The prominent players considered in the market are as mentioned below:
AstraZeneca, Bristol-Myers Squibb Company, Conatus Pharmaceuticals, Galmed Pharmaceuticals, Genfit, Gilead Sciences, Inc., Immuron Ltd, and Intercept Pharmaceuticals, Inc.
North America non-alcoholic steatohepatitis treatment industry is expected to reach USD 23.2 billion by 2032 due to serious complications like cirrhosis and liver cancer if left untreated.
The oral route of administration segment accounted for 63.6% of the market share in 2023 due to several advantages, such as ease of administration, patient compliance, and cost-effectiveness
The non-alcoholic steatohepatitis treatment industry size was USD 5.5 billion in 2023 and is expected to showcase 29.9% CAGR from 2024 to 2032 due to increasing prevalence of metabolic disorders